Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Novartis Expands Swiss Drug Capacity

September 3, 2007 | A version of this story appeared in Volume 85, Issue 36

Novartis is investing roughly $250 million to increase manufacturing capacity in Schweizerhalle, Switzerland, for its portfolio of blood pressure medications, including Diovan, Exforge, and Tekturna. The project will focus on Tekturna, a direct renin inhibitor launched in the U.S. earlier this year and recently approved in Europe under the brand name Rasilez. Last year, Novartis spent $62 million on a new plant in Schweizerhalle to produce the active ingredient in its breast cancer drug Femara. The latest expansion, which will create 60 jobs, is expected to be completed by fall 2008.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.